Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

Aggarwal, Himani; Punekar, Rajeshwari S.; Li, Li; Carter, Gebra Cuyun; Walker, Mark S.

doi:10.1186/s12955-020-01424-x

Table 3 Linear mixed models of Despair, Impaired Ambulation, and Impaired Performance

From: Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States

	Despair^a		Impaired Ambulation^b		Impaired Performance^c
Effect	Estimate (SE)	P-value	Estimate (SE)	P-value	Estimate (SE)	P-value
Intercept	61.22 (9.271)	< 0.0001	52.86 (8.981)	< 0.0001	41.96 (9.271)	0.0001
Time (months) since diagnosis	− 0.15 (0.048)	0.003	− 0.03 (0.026)	0.256	− 0.04 (0.037)	0.241
Treatment: cetuximab±RT (vs. cisplatin±RT)	6.62 (2.010)	0.001	−0.82 (1.570)	0.602	−0.13 (1.703)	0.941
Treatment* time since diagnosis	−0.21 (0.141)	0.129	0.08 (0.092)	0.390	−0.01 (0.140)	0.930
Age at diagnosis	−0.27 (0.084)	0.001	−0.08 (0.065)	0.249	−0.05 (0.067)	0.477
Male (vs. female)	−1.32 (1.702)	0.438	− 1.63 (1.204)	0.175	−0.45 (1.227)	0.713
White (vs. minority/unknown)	2.91 (1.513)	0.055	−0.40 (1.114)	0.720	1.62 (1.133)	0.152
Impaired composite performance status (vs. not impaired)	−0.62 (2.846)	0.829	3.34 (2.146)	0.120	2.30 (2.193)	0.294
Weighted index of comorbid conditions	0.35 (0.875)	0.689	1.33 (0.570)	0.020	0.77 (0.583)	0.189
Smoking status: current or past (vs. never/unknown/undocumented)	1.90 (1.910)	0.321	1.67 (1.398)	0.231	2.36 (1.429)	0.100
Alcohol status	–	0.424	–	0.307	–	0.357
Current or past abuse (vs. never/unknown/undocumented)	−0.82 (1.984)	0.679	1.01 (1.460)	0.490	0.66 (1.491)	0.660
Current or past use (vs. never/unknown/undocumented)	−2.09 (1.633)	0.201	−0.91 (1.184)	0.445	−1.08 (1.209)	0.370
Stage at start: Stage III (vs. Stage IV)	0.53 (1.377)	0.698	−0.60 (1.058)	0.571	−0.02 (1.076)	0.989
Oral (vs. non-oral)	−4.92 (3.910)	0.209	−0.84 (2.822)	0.766	−0.48 (2.892)	0.869
Pharynx (vs. non-pharynx)	−5.00 (3.557)	0.161	−0.61 (2.788)	0.826	−0.92 (2.851)	0.746
Larynx (vs. non-larynx)	−4.30 (3.702)	0.246	−3.84 (2.959)	0.195	−3.27 (3.022)	0.279
HPV test results (positive vs. non-positive)	−6.18 (4.057)	0.128	0.715 (3.091)	0.817	0.62 (3.177)	0.845
P16 test results (positive vs. non-positive)	0.69 (1.976)	0.728	1.528 (1.194)	0.201	1.46 (1.218)	0.231
Feeding tube placement (vs. not placed)	0.060 (1.451)	0.967	0.54 (1.076)	0.613	1.20 (1.097)	0.273
BMI	0.055 (0.109)	0.612	0.08 (0.086)	0.376	0.12 (0.087)	0.155
Insurance	–	0.014	–	0.008	–	0.001
Only public (vs. only private)	4.57 (1.956)	0.020	4.65 (1.424)	0.001	5.70 (1.452)	< 0.0001
Both public and private (vs. only private)	5.53 (1.793)	0.002	3.20 (1.338)	0.017	3.77 (1.365)	0.006
Other/unknown/undocumented (vs. only private)	1.72 (4.638)	0.711	3.66 (3.308)	0.268	5.54 (3.403)	0.104
US region South (vs. non-South)	3.20 (5.737)	0.577	1.69 (6.750)	0.802	−1.57 (7.014)	0.823

Reference level for each comparison is in parentheses
BMI body mass index, HPV human papilloma virus, RT radiation therapy, SE standard error, US United States
^aAnalysis is based on 163 patients and 1048 observations
^bAnalysis is based on 218 patients and 1320 observations
^cAnalysis is based on 218 patients and 1311 observations
*refers to an interaction

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us